PLCL from PolySciTech: Akina used in development of nanoparticles for delivery of SN-38 as colorectal cancer therapy

 

Colon cancer is statistically the third most fatal malignancy worldwide. Almost 50% of patients develop metastatic colon cancer which is a highly fatal condition. Recently, researchers at University of Prishtina (Kosovo), TardigradeNano LLC (California), and San Diego State University used PLCL (cat# AP103) from PolySciTech division of Akina (www.polyscitech.com) along with pluronic to formulate a series of nanoparticles containing SN-38. They tracked the effects of these particles on the gene regulation of colorectal cancer cells with nanoparticles that have a wide pluronic corona or a collapsed one. This study holds promise to improve nanoparticle therapies of cancer in the future. Read more: Koliqi, Rozafa, Arlinda Daka Grapci, Pranvera Breznica Selmani, and Vuk Uskoković. "Gene Expression Effects of the Delivery of SN-38 via Poly (DL-lactide-co-caprolactone) Nanoparticles Comprising Dense and Collapsed Poloxamer Coronae." Journal of Pharmaceutical Innovation (2022): 1-9. https://link.springer.com/article/10.1007/s12247-022-09672-8

“Purpose: SN-38 is an antineoplastic drug with a three orders of magnitude higher activity than its prodrug, irinotecan, a common chemotherapeutic of choice in the treatment of colorectal cancer. A considerable number of genes are known to alter their expression under the influence of free SN-38, but no studies have looked at the gene expression effects of SN-38 delivered via poly(D-L-lactide-co-caprolactone) (PLCL) nanoparticles yet. Method: We evaluated changes to expression levels of genes encoding for ubiquitin D (UBD), fibroblast growth factor 3 (FGF3), histone (HIST), and regulator of cell cycle (RGCC) in SW-480 colon cancer cells in response to free SN-38 and two types of poloxamer-coated PLCL (PEO-PPO-PEO/PLCL) nanoparticles as carriers for SN-38, containing different conformations of the hydrophilic stealth corona: dense or collapsed. Results: Both the free drug and the two drug-loaded nanoformulations upregulated UBD and RGCC and downregulated FGF3 and HIST, which was consistent with the pharmacological activity of SN-38. Still, there was a clear difference in gene expression levels in SW-480 cells depending on whether they were challenged with free SN-38 or with nanoparticles loaded with SN-38. Most critically, the delivery of SN-38 with the nanoparticles prolonged its mode of action and, in the case of genes such as UBD, FGF3, and HIST, provided for a more intense effect on gene expression alteration than that achieved by the drug alone. Conclusions: Nanoparticles comprising the collapsed PEO-PPO-PEO corona produced a more intense effect on gene expression alteration than the nanoparticles with the dense PEO-PPO-PEO corona.”